Albert Stroucken - Baxter International Lead Independent Director

BAX Stock  USD 42.74  0.05  0.12%   

Director

Mr. Albert P.L. Stroucken is Independent Director of the Company. Mr. Stroucken served as Executive Chairman of the Board of OwensIllinois, Inc., a glass packaging company, from January 1 to June 30, 2016, having served as Chairman, President and Chief Executive Officer from 2006 until 2015. From 1998 to 2006, Mr. Stroucken served as President and Chief Executive Officer of H.B. Fuller Company, a manufacturer of adhesives, sealants, coatings, paints and other specialty chemicals. Mr. Stroucken served as Chairman of H.B. Fuller Company from 1999 to 2006. From 1997 to 1998, he was General Manager of the Inorganics Division of Bayer AG. From 1992 to 1997, Mr. Stroucken was Executive Vice President and President of the Industrial Chemicals Division of Bayer Corporation since 2021.
Age 73
Tenure 3 years
Address One Baxter Parkway, Deerfield, IL, United States, 60015
Phone224 948 2000
Webhttps://www.baxter.com
Stroucken previously served as a director of Baxalta and as a director of Shire until its recent acquisition by Takeda Pharmaceutical Company Ltd. Substantial experience leading and operating large, complex corporations and significant financial expertise through his leadership roles with OwensIllinois, Inc. and H.B. Fuller Company as well as through positions at Bayer Corporationrationrationration.

Baxter International Management Efficiency

The company has Return on Asset of 0.0334 % which means that on every $100 spent on assets, it made $0.0334 of profit. This is way below average. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024.
The company has 14.36 B in debt with debt to equity (D/E) ratio of 3.03, meaning that the company heavily relies on borrowing funds for operations. Baxter International has a current ratio of 2.07, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Baxter International until it has trouble settling it off, either with new capital or with free cash flow. So, Baxter International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Baxter International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Baxter to invest in growth at high rates of return. When we think about Baxter International's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Alisa LaskNephros
N/A
Ann CooksonEkso Bionics Holdings
N/A
Stanley SternEkso Bionics Holdings
60
Oliver SpandowNephros
N/A
Thomas SchreckEkso Bionics Holdings
60
Howard PalefksyEkso Bionics Holdings
N/A
Alfred VargasNephros
N/A
Thomas GwydirNephros
N/A
Theodore WangEkso Bionics Holdings
51
Arthur AmronNephros
61
Matthew RosenbergNephros
33
Malcom PersenNephros
60
Ted WangEkso Bionics Holdings
50
Amy WendellEkso Bionics Holdings
56
Dan BorenEkso Bionics Holdings
40
Paul MieyalNephros
45
Jack PeurachEkso Bionics Holdings
48
Marilyn HamiltonEkso Bionics Holdings
64
Andrew HuntWarby Parker
N/A
Moshe PintoNephros
N/A
Charles LiEkso Bionics Holdings
N/A
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois. Baxter International operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 60000 people. Baxter International (BAX) is traded on New York Stock Exchange in USA. It is located in One Baxter Parkway, Deerfield, IL, United States, 60015 and employs 60,000 people. Baxter International is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Baxter International Leadership Team

Elected by the shareholders, the Baxter International's board of directors comprises two types of representatives: Baxter International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Baxter. The board's role is to monitor Baxter International's management team and ensure that shareholders' interests are well served. Baxter International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Baxter International's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Rosenbloom, Executive Counsel
Jacqueline Kunzler, Senior Vice President and Chief Quality Officer
Sebastian Bufalino, Principal Accounting Officer, Corporate VP and Controller
Brik Eyre, Senior Vice President, President - Americas
Heather Knight, Executive Therapies
Talvis Love, Senior Officer
Amy McbrideWendell, Independent Director
Jeanne Mason, Senior Vice President - Human Resources
Brian Stevens, Senior Vice President Chief Accounting Officer, Controller
Kornelis Storm, Independent Director
Karp, Corporate Vice President Controller
Cathy Smith, Independent Director
Marcus Schabacker, Chief Scientific Officer, Corporate Vice President
Thomas Chen, Independent Director
Clare Trachtman, Vice President Investor Relations
Amy Wendell, Independent Director
Peter Hellman, Lead Independent Director
Robert Parkinson, Chairman, CEO and Pres
MS MD, Senior Officer
Giuseppe Accogli, Senior Vice President and Presidentident - Global Businesses
Sean Martin, Corporate Vice President General Counsel
Cristiano Franzi, Senior Vice President and President EMEA
Carole Shapazian, Independent Director
Andrew Frye, Senior Vice President and President APAC
Nancy Schlichting, Independent Director
Robert Hombach, CFO and Corporate VP
Michael Mahoney, Independent Director
Jill Schaaf, Corporate Vice President and President - Renal
Stacey Eisen, Senior Communications
Ludwig Hantson, Corporate VP and President of BioScience
Gail Fosler, Independent Director
John Forsyth, Independent Director
Timothy Lawrence, Corporate VP of Operations
Uma Chowdhry, Independent Director
Scott Pleau, Corporate Vice President - Operations
David Wilkes, Independent Director
Albert Stroucken, Lead Independent Director
Paul Vibert, President Corporate Vice President - International
James Borzi, Senior Vice President Chief Supply Chain Officer
James Gavin, Independent Director
Blake Devitt, Independent Director
Reazur Rasul, Executive Technologies
Jose Almeida, Chairman of the Board, President, Chief Executive Officer
James Saccaro, Chief Financial Officer, Executive Vice President
Thomas Stallkamp, Lead Independent Director
David Scharf, Corporate VP, General Counsel and Corporate Secretary
Robert Felicelli, Corporate Vice President - Quality
Wayne Hockmeyer, Independent Director
Patricia Morrison, Independent Director
Joel Grade, Executive CFO
Stephen Oesterle, Independent Director
Munib Islam, Independent Director

Baxter Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Baxter International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Baxter International

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Baxter International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Baxter International will appreciate offsetting losses from the drop in the long position's value.

Moving together with Baxter Stock

  0.8BSX Boston Scientific Corp Financial Report 24th of April 2024 PairCorr
  0.77COO Cooper Companies Financial Report 6th of June 2024 PairCorr

Moving against Baxter Stock

  0.73TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.7MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.63PIIIW P3 Health PartnersPairCorr
  0.62PHG Koninklijke Philips Financial Report 22nd of April 2024 PairCorr
  0.6MBIO Mustang Bio Report 3rd of April 2024 PairCorr
The ability to find closely correlated positions to Baxter International could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Baxter International when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Baxter International - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Baxter International to buy it.
The correlation of Baxter International is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Baxter International moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Baxter International moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Baxter International can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Baxter International offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Baxter International's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Baxter International Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Baxter International Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Baxter International. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Baxter Stock please use our How to Invest in Baxter International guide.
Note that the Baxter International information on this page should be used as a complementary analysis to other Baxter International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Baxter Stock analysis

When running Baxter International's price analysis, check to measure Baxter International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baxter International is operating at the current time. Most of Baxter International's value examination focuses on studying past and present price action to predict the probability of Baxter International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Baxter International's price. Additionally, you may evaluate how the addition of Baxter International to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Baxter International's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Baxter International. If investors know Baxter will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Baxter International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.338
Dividend Share
1.16
Earnings Share
(0.15)
Revenue Per Share
29.275
Quarterly Revenue Growth
0.037
The market value of Baxter International is measured differently than its book value, which is the value of Baxter that is recorded on the company's balance sheet. Investors also form their own opinion of Baxter International's value that differs from its market value or its book value, called intrinsic value, which is Baxter International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Baxter International's market value can be influenced by many factors that don't directly affect Baxter International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Baxter International's value and its price as these two are different measures arrived at by different means. Investors typically determine if Baxter International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Baxter International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.